XTX Topco Ltd Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

XTX Topco Ltd acquired a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 52,344 shares of the biotechnology company's stock, valued at approximately $562,000. XTX Topco Ltd owned 0.06% of Anavex Life Sciences at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AVXL. Invesco Ltd. grew its position in Anavex Life Sciences by 2,419.8% in the fourth quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock valued at $6,606,000 after acquiring an additional 590,639 shares during the last quarter. Pier Capital LLC acquired a new position in Anavex Life Sciences during the 4th quarter worth approximately $4,746,000. Essential Planning LLC. bought a new position in Anavex Life Sciences in the 4th quarter valued at approximately $4,437,000. Wellington Management Group LLP bought a new stake in shares of Anavex Life Sciences during the fourth quarter worth $1,704,000. Finally, Heartland Advisors Inc. acquired a new position in shares of Anavex Life Sciences during the fourth quarter worth $1,674,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AVXL has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital reiterated a "buy" rating and set a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Stock Up 0.6 %

Shares of NASDAQ AVXL traded up $0.06 during trading on Friday, reaching $9.51. The company had a trading volume of 138,371 shares, compared to its average volume of 1,231,915. The stock has a market cap of $808.53 million, a P/E ratio of -17.31 and a beta of 0.80. The company's fifty day moving average price is $8.77 and its 200-day moving average price is $8.72. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.